Dyne Therapeutics Inc Dossier - Source-backed chat

Dyne Therapeutics Inc

DYNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.07

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $15.82Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $3B

Enterprise Value $2.5B

Shares Outstanding 165.7M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Dyne Therapeutics is a clinical-stage biotechnology company poised for a major transition to a commercial-stage entity. The company's proprietary FORCE platform has achieved clinical validation through its two lead programs: z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy (DMD) and z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1). With the recent submission of a Biologics License Application (BLA) for z-rostudirsen in May 2026 and a robust cash runway of $972.2 million extending into Q1 2028, Dyne is well-capitalized to execute its near-term regulatory and clinical milestones. The platform's potential is further de-risked by high big-pharma interest in the antibody-oligonucleotide conjugate space, highlighted by Novartis's $12 billion acquisition of competitor Avidity Biosciences.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$39.40

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$17.0020%

The FDA raises safety concerns regarding z-rostudirsen's narrow therapeutic window or high-dose tolerability, delaying approval or requiring additional clinical data from the Phase 3 FORZETTO trial. Competitor Avidity Biosciences dominates the DM1 market, making Dyne's accelerated approval pathway for z-basivarsen redundant or highly restricted. Increased R&D and commercial launch preparation expenses accelerate cash burn, forcing a highly dilutive equity raise in late 2027.

Base CaseCentral scenario

$39.4050%

Matches the consensus mean

Z-rostudirsen receives FDA Accelerated Approval with a standard or slightly delayed timeline, leading to a U.S. launch in mid-2027. Z-basivarsen continues to progress through its Phase 3 HARMONIA trial and ACHIEVE REC, with positive topline data in Q1 2027 supporting a BLA filing in late 2027. The company maintains disciplined spending, keeping its cash runway intact into early 2028, with the stock trading close to the consensus target of $38.25.

Bull CaseUpside scenario

$50.0030%

The FDA grants Priority Review for z-rostudirsen, leading to Accelerated Approval and a highly successful U.S. launch in Q1 2027. Concurrently, z-basivarsen's ACHIEVE REC topline data in Q1 2027 shows best-in-class efficacy and safety, paving the way for a Q3 2027 BLA submission. The FORCE platform's expansion into CNS indications (e.g., tauopathies) is validated by preclinical data, attracting a lucrative global partnership or a premium acquisition offer exceeding $50.00 per share.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Validated FORCE platform delivering targeted therapeutics directly to skeletal, cardiac, and smooth muscle tissues.
Z-rostudirsen BLA submitted in May 2026 for DMD exon 51 skipping, targeting a potential Q1 2027 U.S. launch.
Strong balance sheet with $972.2 million in cash and marketable securities as of March 31, 2026, providing runway into Q1 2028.
High strategic value and M&A optionality in the antibody-oligonucleotide conjugate space, validated by peer transactions.

Key Investment Risks

Clinical and regulatory risks associated with FDA's review of the z-rostudirsen BLA and the accelerated approval pathway.
Safety and tolerability concerns, specifically potential serious adverse events (e.g., malaise, fever) at higher therapeutic doses.
Intense competition from established players like Sarepta Therapeutics and fast-moving peers like Wave Life Sciences.

Thesis Invalidation Triggers

FDA rejection or a Complete Response Letter (CRL) for the z-rostudirsen BLA.
Failure of the ACHIEVE REC to meet its primary hand-opening time (myotonia) endpoint in Q1 2027.
Severe safety signals in the Phase 3 FORZETTO or HARMONIA trials leading to clinical holds.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.